BioSpace News Archive

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023 at 2:15pm Pacific time.

Nevro Corp. (NYSE: NVRO) today announced that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm Pacific Time / 6:45 pm Eastern Time.

Sirnaomics Ltd. and its affiliates and subsidiaries, a leading biopharmaceutical company in discovery and development of RNAi therapeutics, celebrated Sirnaomics’ 15th anniversary of RNAi therapeutic innovation globally, along with the grand opening of the new headquarters and laboratories for its US subsidiary in Germantown, Maryland, on Dec. 15, 2022.

The U.S. District Court for the Western District of Oklahoma entered a consent decree against Qualgen LLC, an outsourcing facility with a history of violations.

Lipella Pharmaceuticals, Inc. (“Lipella,” “our, “us” or the “Company”) today announced the pricing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per share.

XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, today announced a strategic collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), to discover novel treatment candidates for non-small cell lung cancer (NSCLC).

scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, announced the appointment of Rachael Nokes as Chief Financial Officer.

Vaxart, Inc. announced that it has appointed Phillip Lee as its Chief Financial Officer, effective immediately.

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC- 42344 in its Phase 1 study.